Dongwha Pharm.Co.Ltd Crecimiento futuro
Future controles de criterios 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Dongwha Pharm.Co.Ltd.
Información clave
n/a
Tasa de crecimiento de los beneficios
n/a
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Pharmaceuticals | 38.2% |
| Tasa de crecimiento de los ingresos | n/a |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | None |
| Última actualización | n/a |
Actualizaciones recientes sobre el crecimiento futuro
No hay actualizaciones
Recent updates
Dongwha Pharm.Co.Ltd's (KRX:000020) Promising Earnings May Rest On Soft Foundations
Mar 26
Is Dongwha Pharm.Co.,Ltd (KRX:000020) A Smart Pick For Income Investors?
Apr 28These 4 Measures Indicate That Dongwha Pharm.Co.Ltd (KRX:000020) Is Using Debt Safely
Mar 11Dongwha Pharm.Co.,Ltd (KRX:000020) Has A ROE Of 8.6%
Feb 22Is Dongwha Pharm.Co.Ltd's (KRX:000020) Share Price Gain Of 102% Well Earned?
Feb 07Should Dongwha Pharm.Co.,Ltd (KRX:000020) Be Part Of Your Dividend Portfolio?
Jan 23Is Dongwha Pharm.Co.,Ltd (KRX:000020) Popular Amongst Insiders?
Jan 08
Dongwha Pharm.Co.,Ltd (KRX:000020) Pays A ₩120 Dividend In Just Four Days
Dec 24We're Not Counting On Dongwha Pharm.Co.Ltd (KRX:000020) To Sustain Its Statutory Profitability
Dec 19Is Dongwha Pharm.Co.Ltd (KRX:000020) Using Too Much Debt?
Dec 04Can Dongwha Pharm.Co.,Ltd (KRX:000020) Improve Its Returns?
Nov 19En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como Dongwha Pharm.Co.Ltd no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.
Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.
Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 6/30/2024 | 405,746 | 13,902 | -15,571 | 12,915 | N/A |
| 3/31/2024 | 380,574 | 17,888 | 4,636 | 30,375 | N/A |
| 12/31/2023 | 361,109 | 27,438 | 2,821 | 29,167 | N/A |
| 9/30/2023 | 361,326 | 29,155 | 13,526 | 36,468 | N/A |
| 6/30/2023 | 357,324 | 29,177 | 6,752 | 29,906 | N/A |
| 3/31/2023 | 354,552 | 27,685 | 6,195 | 25,941 | N/A |
| 12/31/2022 | 340,426 | 20,383 | 9,129 | 29,221 | N/A |
| 9/30/2022 | 332,285 | 22,907 | 23,344 | 44,420 | N/A |
| 6/30/2022 | 317,901 | 17,410 | 18,460 | 42,210 | N/A |
| 3/31/2022 | 306,485 | 17,660 | 14,831 | 43,713 | N/A |
| 12/31/2021 | 293,018 | 17,870 | 11,257 | 36,031 | N/A |
| 9/30/2021 | 285,371 | 19,928 | -15,293 | 33,076 | N/A |
| 6/30/2021 | 282,868 | 31,238 | -9,675 | 33,484 | N/A |
| 3/31/2021 | 276,899 | 31,693 | 3,101 | 38,469 | N/A |
| 12/31/2020 | 272,075 | 28,508 | 17,582 | 52,228 | N/A |
| 9/30/2020 | 286,746 | 28,405 | 34,345 | 46,441 | N/A |
| 6/30/2020 | 294,395 | 16,884 | 38,711 | 44,238 | N/A |
| 3/31/2020 | 299,490 | 9,533 | 26,638 | 32,360 | N/A |
| 12/31/2019 | 307,150 | 9,116 | 7,779 | 13,285 | N/A |
| 9/30/2019 | 299,195 | 4,881 | 9,447 | 10,561 | N/A |
| 6/30/2019 | 299,893 | 5,823 | -339 | 3,123 | N/A |
| 3/31/2019 | 304,302 | 7,202 | -17,386 | -14,327 | N/A |
| 12/31/2018 | 306,603 | 10,069 | -8,061 | -4,360 | N/A |
| 12/31/2017 | 258,882 | 47,009 | N/A | -16,520 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Insufficient data to determine if A000020's forecast earnings growth is above the savings rate (2.6%).
Beneficios vs. Mercado: Insufficient data to determine if A000020's earnings are forecast to grow faster than the KR market
Beneficios de alto crecimiento: Insufficient data to determine if A000020's earnings are expected to grow significantly over the next 3 years.
Ingresos vs. Mercado: Insufficient data to determine if A000020's revenue is forecast to grow faster than the KR market.
Ingresos de alto crecimiento: Insufficient data to determine if A000020's revenue is forecast to grow faster than 20% per year.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Insufficient data to determine if A000020's Return on Equity is forecast to be high in 3 years time